Apple Extends Qualcomm Patent Licensing Deal 
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
H&M Q3 Profit Beats Estimates as Margins Improve 
Oil Prices Surge as U.S.-Iran Diplomacy Hopes Fade 
Japan Private-Sector Growth Slows as Domestic Demand Weakens 
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit 
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
Microsoft Stock Upgraded as Stifel Sees Stronger Azure Growth 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh 
China’s ‘Lipstick King’ Says AI Won’t Replace Livestream Hosts 
Gold Drops Over 1% as Dollar, Treasury Yields Surge on Fed Rate Hike Bets 
US Backs Musk in Fight Against EU’s €120 Million X Fine 
Goldman Sachs Names Simon Lyons UK Investment Banking Co-Head 
Gold Prices Fall as Treasury Yields Rise on Fed Rate Hike Bets 
Add as a preferred source on Google
Samsung Biologics and Novartis International AG signed a contract manufacturing organization deal, and this was announced on Tuesday, June 7. The deal is worth $81 million.
According to The Korea Herald, the South Korean biotech company signed an intent letter for the CMO with the Swiss multinational pharmaceutical corporation. The agreement was announced via Samsung Biologics’ regulatory filing that also revealed that the companies signed the initial contract late last week.
Based on the report, the amount of the contract is equivalent to 6.41% of Samsung Biologics’ annual sales last year, which reached KRW1.57 trillion or around $1.25 billion. Then again, it was not mentioned which of Novartis’ biopharmaceutical products Samsung Biologics is producing under the CMO agreement.
The Korean biotech firm said that it would be releasing more deals in the future after both parties signed the main contract for their CMO partnership. The collab is said to be the first time Samsung Biologics is securing a deal from the Swiss pharmaceutical company.
“The letter of intent was the first contract between the two firms,” an official of Samsung Biologics stated. “We look forward to continuing to have cooperative relations through this deal in the future.”
The Korea Economic Daily reported that the latest deal increased Samsung Biologics’ total for CMO contracts to $400 million. The company has so far won orders from other multinational pharma firms such as GSK plc that is formerly known as GlaxoSmithKline plc, and Eli Lilly & Co. this year. In comparison, the firm was able to secure $1 billion worth of CMO contracts in 2021.
The South Korean CMO drugmaker obtained contracts from the top pharmaceutical firms in the world, including Bristol Myers Squibb, Roche, Johnson & Johnson, and Merck & Co. It was added that Samsung Biologics also has a contract with Gilead Sciences Inc. in the US.
Meanwhile, Samsung Biologics has been mostly manufacturing antibody treatments recently instead of cell-gene therapy (CGT). It has built up production facilities to make the drug substance for the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines in its plant.
